Featured Research

from universities, journals, and other organizations

New investigational drug holds promise for combatting deadly mucormycosis infections

Date:
February 6, 2014
Source:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Summary:
With very few treatment options available to fight deadly mucormycosis infections, a new study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

Related Articles


An LA BioMed research team reported in an online, ahead-of-print study in the Antimicrobial Agents and Chemotherapy journal that the investigational drug isavuconazole was as effective in reducing mucormycosis infections in disease models as the most widely used treatment currently on the market, high-dose liposomal amphotericin B. Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of severe invasive and life-threatening fungal infections. It is currently in phase 3 of clinical development.

"Expanding the options for fighting these deadly infections is especially important for patients who can't tolerate current treatments or whose infections may not respond to the antifungals on the market today," said Ashraf S. Ibrahim, PhD, an LA BioMed lead researcher and the corresponding author for the study. "With such a limited number of treatments available, developing new therapies is critical to increasing the number of people who survive these extremely lethal infections. "

Patients with weakened immune systems, hyperglycemia, acidosis (diabetic ketoacidosis or other forms of acidosis), malnutrition, or trauma patients are at increased risk of mucormycosis infection. Despite the current treatments and surgeries available to treat mucormycosis, more than half of patients with the infections die.

"Clearly, new strategies for preventing and treating mucormycosis are urgently needed," the researchers concluded.

They examined the most common form of this deadly infection, mucormycosis due to Rhizopus delemar, and concluded that their results support the further development of isavuconazole.


Story Source:

The above story is based on materials provided by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. G. Luo, T. Gebremariam, H. Lee, J. E. Edwards, L. Kovanda, A. S. Ibrahim. Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis. Antimicrobial Agents and Chemotherapy, 2014; DOI: 10.1128/AAC.02301-13

Cite This Page:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "New investigational drug holds promise for combatting deadly mucormycosis infections." ScienceDaily. ScienceDaily, 6 February 2014. <www.sciencedaily.com/releases/2014/02/140206133828.htm>.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). (2014, February 6). New investigational drug holds promise for combatting deadly mucormycosis infections. ScienceDaily. Retrieved March 26, 2015 from www.sciencedaily.com/releases/2014/02/140206133828.htm
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "New investigational drug holds promise for combatting deadly mucormycosis infections." ScienceDaily. www.sciencedaily.com/releases/2014/02/140206133828.htm (accessed March 26, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, March 26, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Ready to Pass Medicare Doc Bill

House Ready to Pass Medicare Doc Bill

AP (Mar. 26, 2015) In rare bipartisan harmony, congressional leaders pushed a $214 billion bill permanently blocking physician Medicare cuts toward House passage Thursday, moving lawmakers closer to resolving a problem that has plagued them for years. (March 26) Video provided by AP
Powered by NewsLook.com
HIV Outbreak Prompts Public Health Emergency In Indiana

HIV Outbreak Prompts Public Health Emergency In Indiana

Newsy (Mar. 26, 2015) Indiana Gov. Mike Pence says he will bring additional state resources to help stop the epidemic. Video provided by Newsy
Powered by NewsLook.com
AAA: Distracted Driving a Serious Teen Problem

AAA: Distracted Driving a Serious Teen Problem

AP (Mar. 25, 2015) While distracted driving is not a new problem for teens, new research from the AAA Foundation for Traffic Safety says it&apos;s much more serious than previously thought. (March 25) Video provided by AP
Powered by NewsLook.com
Obama: Affordable Care Act 'saving Lives'

Obama: Affordable Care Act 'saving Lives'

AP (Mar. 25, 2015) Speaking at a White House event marking the fifth anniversary of the Affordable Care Act, President Barack Obama says the law is "saving lives that touch all of us." (March 25) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins